Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | sEphB4-HSA |
| Trade Name | |
| Synonyms | |
| Drug Descriptions |
sEphB4-HSA is a fusion protein that consists of the extracellular domain of human ephrin type-B receptor 4 (EphB4) and human serum albumin (HSA), which acts as a decoy to inhibit EphB4 signaling, leading to inhibition of tumor cell growth (PMID: 23721559, PMID: 25148033, PMID: 27941840). |
| DrugClasses | EPHB4 Inhibitor 6 |
| CAS Registry Number | NA |
| NCIT ID | C102569 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + sEphB4-HSA | Bevacizumab sEphB4-HSA | 0 | 0 |
| Cetuximab + sEphB4-HSA | Cetuximab sEphB4-HSA | 0 | 1 |
| Cytarabine + sEphB4-HSA | Cytarabine sEphB4-HSA | 0 | 1 |
| Paclitaxel + sEphB4-HSA | Paclitaxel sEphB4-HSA | 0 | 0 |
| Pembrolizumab + sEphB4-HSA | Pembrolizumab sEphB4-HSA | 0 | 4 |
| sEphB4-HSA | sEphB4-HSA | 0 | 3 |
| sEphB4-HSA + Vincristine sulfate liposome | Vincristine sulfate liposome sEphB4-HSA | 0 | 1 |